When is tucatinib/tucatinib expected to be launched in China?

Tucatinib is a highly selective HER2 tyrosine kinase inhibitor, mainly used to treat HER2-positive breast cancer, especially for metastatic and advanced cases. Currently, the drug is developed by Seattle Genetics in the United States. It has been approved for marketing in many countries and regions, including the United States, the European Union, the United Kingdom, Canada and Japan, and has been included in the important drug list for the treatment of HER2-positive breast cancer. However, as of now, tucatinib has not been officially approved for marketing by the National Medical Products Administration (NMPA) in mainland China, and therefore has not been included in the Chinese National Medical Insurance List.

There is currently no precise public information about its launch time in China. Although there is news that some multinational pharmaceutical companies are promoting the registration process of the drug in China, it is expected that it may be difficult to quickly enter the domestic market in the short term due to the multiple links involved such as clinical data submission, approval cycle, and indication confirmation. Usually, the approval cycle of foreign innovative drugs in China is affected by various factors, especially in the absence of local clinical research data. The time to market often lags behind that of developed countries in Europe and the United States by several years.

However, considering that China has accelerated the review of innovative anti-cancer drugs in recent years, if tucatinib enters the "priority review" or "breakthrough therapy" channel in the future, its marketing process may be relatively accelerated. On the other hand, as the public pays increasing attention to the treatment of HER2-positive metastatic breast cancer, the prospects for the drug to be launched in China are generally promising, but the timing is still uncertain. During this period, if patients need to use tucatinib, they must obtain it through legal and compliant international medical channels, and should use it with caution under the guidance of professional doctors to avoid information asymmetry or channel risks affecting drug safety.

Reference materials:https://www.tukysa.com/